Breaking News, Collaborations & Alliances

Essential Pharma Signs Strategic Agreement with AGC Biologics

AGC Biologics will support the process development, scale-up & manufacturing of Hu14.18 as Essential Pharma plans to commence clinical activities.

Author Image

By: Charlie Sternberg

Associate Editor

Essential Pharma’s rare disease business has signed a strategic agreement with AGC Biologics under which AGC Biologics will produce Hu1418K322A (Hu14.18), a humanized monoclonal antibody being developed for Essential Pharma for the treatment of high-risk neuroblastoma (HRNB).   Per the agreement, AGC Biologics will support the process development, scale-up and manufacturing as Essential Pharma plans to commence clinical activities and ongoing regulatory agency interactions over the coming mont...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters